UPDATE: H.C. Wainwright & Co. Initiates Coverage on Prana Biotechnology Limited with Buy Rating, $20.50 PT Ahead of Results Announcement

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Tuesday, H.C. Wainwright & Co. analyst George B. Zavoico initiated coverage on

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Prana Biotechnology Limited

(NASDAQ: PRAN) with a Buy rating and $20.50 price target.In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Prana Biotechnology Ltd. with a BUY recommendation and a $20.50 one-year price target. In our view, two ongoing randomized, double-blind Phase IIa trials of Prana's lead drug candidate, PBT2, in Huntington's and Alzheimer's diseases (HD and AD, respectively) are likely to deliver favorable results soon. We note that Prana was granted a trading halt on the Australian Securities Exchange yesterday (Feb. 17) due to a pending announcement of top line results of its HD trial, called Reach2HD. The results are likely to be announced today or tomorrow. Prana guided to announcing top line results of the AD trial, called IMAGINE, in mid-March.”Prana Biotechnology Limited closed on Friday at $7.25.